Anthera Pharmaceuticals Inc. (NASDAQ:ANTH)’s share price was down 4% during trading on Wednesday . The stock traded as low as $2.86 and last traded at $2.90, with a volume of 193,287 shares changing hands. The stock had previously closed at $3.02.

Several equities analysts recently commented on ANTH shares. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Thursday, May 12th. Jefferies Group reiterated a “buy” rating on shares of Anthera Pharmaceuticals in a report on Thursday, June 9th. FBR & Co reiterated a “hold” rating on shares of Anthera Pharmaceuticals in a report on Monday, June 20th. Finally, HC Wainwright started coverage on shares of Anthera Pharmaceuticals in a report on Friday, July 8th. They set a “buy” rating and a $10.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Anthera Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $9.58.

The company’s 50-day moving average is $3.15 and its 200 day moving average is $3.43. The stock’s market cap is $119.31 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.04. Analysts predict that Anthera Pharmaceuticals Inc. will post ($1.37) earnings per share for the current fiscal year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.